Patients with myelodysplastic syndrome (MDS) who are resistant to azacitidine (AZA) have quiescent bone marrow hematopoietic progenitor cells (HPCs), and a smaller proportion of these cells undergo active cell cycle progression in AZA-resistant patients compared with responders, according to Australian investigators.
Researchers still do not understand the molecular mechanisms that lead to resistance and why those who do not improve after AZA treatment often relapse within two years, but these